Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1527-1532

  Ahmad, Zahoor ^a   Fraig, Mostafa M ^c   Bisson, Gregory P ^d   Nuermberger, Eric L ^a,b   Grosset, Jacques H ^a   Karakousis, Petros C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c University of Louisville School of Medicine   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; GUINEA PIG; INTRACELLULAR BACTERIUM; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; GUINEA PIGS; LUNG; MICE; PYRAZINAMIDE; TUBERCULOSIS;

EID: 79953193416     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01524-10     Document Type: Article

References (54)

1. Ahmad, Z., et al. 2009. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J. Infect. Dis. 200:1136-1143.
2. Ahmad, Z., et al. 2010. Comparison of the "Denver regimen" against acute tuberculosis in the mouse and guinea pig. J. Antimicrob. Chemother. 65:729-734.
3. Almeida, D., et al. 2009. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob. Agents Chemother. 53:4178-4184.
4. Barnes, P. F., et al. 1990. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J. Immunol. 145:149-154. (Pubitemid 20217394)
5. British Medical Research Council. 1986. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. East and Central African/British Medical Research Council Fifth Collaborative Study. Tubercle 67:5-15.
6. British Medical Research Council. 1991. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am. Rev. Respir. Dis. 143:700-706.
7. British Medical Research Council. 1986. Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. Am. Rev. Respir. Dis. 133:779-783.
8. Canetti, G. 1965. Present aspects of bacterial resistance in tuberculosis. Am. Rev. Respir. Dis. 92:687-703.
9. Choi, H. S., P. R. Rai, H. W. Chu, C. Cool, and E. D. Chan. 2002. Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 166:178-186.
10. Conte, J. E., Jr., J. A. Golden, S. Duncan, E. McKenna, and E. Zurlinden. 1999. Intrapulmonary concentrations of pyrazinamide. Antimicrob. Agents Chemother. 43:1329-1333.
11. Crowle, A. J., R. Dahl, E. Ross, and M. H. May. 1991. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect. Immun. 59:1823-1831.
12. Dessau, F. I., R. L. Yeager, F. J. Burger, and J. H. Williams. 1952. Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig. Am. Rev. Tuberc. 65:519-522.
13. Dickinson, J. M., and D. A. Mitchison. 1970. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 51:82-94.
14. Flynn, J., and J. Chan. 2004. Animal models of tuberculosis, p. 237-250. In W. Rom and S. Garay (ed.), Tuberculosis, 2nd ed. Lippincott/The Williams & Wilkins Co., Philadelphia, PA.
15. Flynn, J. L., et al. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-2254.
16. Gomez, J. E., and J. D. McKinney. 2004. Persistence and drug tolerance, p. 101-114. In W. N. Rom and S. M. Garay (ed.), Tuberculosis, 2nd ed. Lippincott/The Williams & Wilkins Co., Philadelphia, PA.
17. Grosset, J., C. Truffot-Pernot, C. Lacroix, and B. Ji. 1992. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob. Agents Chemother. 36:548-551.
18. Gumbo, T., C. S. Dona, C. Meek, and R. Leff. 2009. Pharmacokinetics- pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob. Agents Chemother. 53:3197-3204.
19. Haapanen, J. H., I. Kass, G. Gensini, and G. Middlebrook. 1959. Studies on the gaseous content of tuberculous cavities. Am. Rev. Respir. Dis. 80:1-5.
20. Heifets, L., M. Higgins, and B. Simon. 2000. Pyrazinamide is not active against Mycobacterium tuberculosis residing in cultured human monocyte-derived macrophages. Int. J. Tuberc. Lung Dis. 4:491-495.
21. Hoff, D. R., et al. 2008. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:4137-4140.
22. Jindani, A., V. R. Aber, E. A. Edwards, and D. A. Mitchison. 1980. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am. Rev. Respir. Dis. 121:939-949.
23. Klinkenberg, L. G., L. A. Sutherland, W. R. Bishai, and P. C. Karakousis. 2008. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J. Infect. Dis. 198:275-283.
24. Konno, K., F. M. Feldmann, and W. McDermott. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am. Rev. Respir. Dis. 95:461-469.
25. Kushner, S., et al. 1952. Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds. J. Am. Chem. Soc. 74:3617-3621.
26. Lecoeur, H. F., P. H. Lagrange, C. Truffot-Pernot, M. Gheorghiu, and J. Grosset. 1989. Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice. Clin. Exp. Immunol. 76:458-462.
27. Lecoeur, H. F., C. Truffot-Pernot, and J. H. Grosset. 1989. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am. Rev. Respir. Dis. 140:1189-1193.
28. Lenaerts, A. J., et al. 2007. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51:3338-3345.
29. McMurray, D. N. 1994. Guinea pig model of tuberculosis, p. 135-147. In B. Bloom (ed.), Tuberculosis: pathogenesis, protection, and control. American Society for Microbiology, Washington, DC.
30. Mitchison, D. A. 1985. The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66:219-225. (Pubitemid 16150082)
31. Newport, M. J., et al. 1996. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335: 1941-1949.
32. Ordway, D. J., et al. 2010. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob. Agents Chemother. 54:1820-1833.
33. Pasipanodya, J. G., and T. Gumbo. 2010. Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. Antimicrob. Agents Chemother. 54:2847-2854.
34. Peloquin, C. A., et al. 1997. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob. Agents Chemother. 41:2670-2679.
35. Raynaud, C., et al. 1999. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity. Microbiology 145(Pt. 6):1359-1367. (Pubitemid 29294921)
36. Rullas, J., et al. 2010. Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrob. Agents Chemother. 54:2262-2264.
37. Salfinger, M., A. J. Crowle, and L. B. Reller. 1990. Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. J. Infect. Dis. 162:201-207.
38. Schon, T., et al. 2004. Local production of nitric oxide in patients with tuberculosis. Int. J. Tuberc. Lung Dis. 8:1134-1137.
39. Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667.
40. Shang, S., et al. 2011. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob. Agents Chemother. 55:124-131.
41. Steele, M. A., and R. M. Des Prez. 1988. The role of pyrazinamide in tuberculosis chemotherapy. Chest 94:845-850.
42. Steenken, W., Jr., and E. Wolinsky. 1954. The antituberculous activity of pyrazinamide in vitro and in the guinea pig. Am. Rev. Tuberc. 70:367-369.
43. Sturgill-Koszycki, S., et al. 1994. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 263:678-681.
44. Vandal, O. H., C. F. Nathan, and S. Ehrt. 2009. Acid resistance in Mycobacterium tuberculosis. J. Bacteriol. 191:4714-4721.
45. Vandal, O. H., L. M. Pierini, D. Schnappinger, C. F. Nathan, and S. Ehrt. 2008. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat. Med. 14:849-854.
46. Vandiviere, H. M., W. E. Loring, I. Melvin, and S. Willis. 1956. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am. J. Med. Sci. 232:30-37.
47. Via, L. E., et al. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect. Immun. 76:2333-2340.
48. Wade, M. M., and Y. Zhang. 2004. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J. Med. Microbiol. 53:769-773.
49. Yeager, R. L., W. G. Munroe, and F. I. Dessau. 1952. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65:523-546.
50. Zhang, Y., and D. Mitchison. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7:6-21.
51. Zhang, Y., S. Permar, and Z. Sun. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:42-49.
52. Zhang, Y., A. Scorpio, H. Nikaido, and Z. Sun. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Bacteriol. 181:2044-2049. (Pubitemid 29164956)
53. Zhang, Y., M. M. Wade, A. Scorpio, H. Zhang, and Z. Sun. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J. Antimicrob. Chemother. 52:790-795.
54. Zimhony, O., J. S. Cox, J. T. Welch, C. Vilcheze, and W. R. Jacobs, Jr. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat. Med. 6:1043-1047.